These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34278402)

  • 1. SARS-CoV-2 M
    Grifagni D; Calderone V; Giuntini S; Cantini F; Fragai M; Banci L
    Chem Commun (Camb); 2021 Aug; 57(64):7910-7913. PubMed ID: 34278402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc
    Panchariya L; Khan WA; Kuila S; Sonkar K; Sahoo S; Ghoshal A; Kumar A; Verma DK; Hasan A; Khan MA; Jain N; Mohapatra AK; Das S; Thakur JK; Maiti S; Nanda RK; Halder R; Sunil S; Arockiasamy A
    Chem Commun (Camb); 2021 Sep; 57(78):10083-10086. PubMed ID: 34514483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode.
    Lockbaum GJ; Henes M; Lee JM; Timm J; Nalivaika EA; Thompson PR; Kurt Yilmaz N; Schiffer CA
    Biochemistry; 2021 Oct; 60(39):2925-2931. PubMed ID: 34506130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 M
    Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M
    Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
    Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33503819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the inhibition of the HCoV-NL63 main protease M
    Xu J; Zhu Q; Li W; Yin X; Li J
    Biochem Biophys Res Commun; 2024 Sep; 724():150231. PubMed ID: 38852502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
    Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
    Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-covalent SARS-CoV-2 M
    Rossetti GG; Ossorio MA; Rempel S; Kratzel A; Dionellis VS; Barriot S; Tropia L; Gorgulla C; Arthanari H; Thiel V; Mohr P; Gamboni R; Halazonetis TD
    Sci Rep; 2022 Feb; 12(1):2505. PubMed ID: 35169179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300.
    Davis DA; Bulut H; Shrestha P; Yaparla A; Jaeger HK; Hattori SI; Wingfield PT; Mieyal JJ; Mitsuya H; Yarchoan R
    mBio; 2021 Aug; 12(4):e0209421. PubMed ID: 34399606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of rosmarinic acid inhibitory mechanism on SARS-CoV-2 main protease.
    Li Q; Zhou X; Wang W; Xu Q; Wang Q; Li J
    Biochem Biophys Res Commun; 2024 Sep; 724():150230. PubMed ID: 38865813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
    Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
    J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
    Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
    Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zinc thiotropolone combinations as inhibitors of the SARS-CoV-2 main protease.
    DeLaney C; Sheng Y; Pectol DC; Vantansever E; Zhang H; Bhuvanesh N; Salas I; Liu WR; Fierke CF; Darensbourg MY
    Dalton Trans; 2021 Sep; 50(35):12226-12233. PubMed ID: 34396374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved SARS-CoV-2 M
    Vuong W; Fischer C; Khan MB; van Belkum MJ; Lamer T; Willoughby KD; Lu J; Arutyunova E; Joyce MA; Saffran HA; Shields JA; Young HS; Nieman JA; Tyrrell DL; Lemieux MJ; Vederas JC
    Eur J Med Chem; 2021 Oct; 222():113584. PubMed ID: 34118724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.
    Kneller DW; Phillips G; Weiss KL; Zhang Q; Coates L; Kovalevsky A
    J Med Chem; 2021 Apr; 64(8):4991-5000. PubMed ID: 33755450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural stability of the SARS-CoV-2 main protease: Can metal ions affect function?
    Kozak JJ; Gray HB; Garza-López RA
    J Inorg Biochem; 2020 Oct; 211():111179. PubMed ID: 32736274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.
    Padhi AK; Tripathi T
    Biochem Biophys Res Commun; 2021 May; 555():147-153. PubMed ID: 33813274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2.
    Chen J; Zhang Y; Zeng D; Zhang B; Ye X; Zeng Z; Zhang XK; Wang Z; Zhou H
    Biochem Biophys Res Commun; 2022 Feb; 591():118-123. PubMed ID: 35007835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.